Recent Advances in Cervical Cancer Treatment
The study demonstrated statistically significant and clinically meaningful PFS and OS improvements with the pembrolizumab‑containing regimen compared with placebo
Cervical cancer refers to the malignant transformation of cervical epithelial or glandular cells, primarily attributed to persistent infection with high‑risk human papillomavirus (HPV) genotypes. Recurrent or metastatic cervical cancer is characterized by an unfavorable prognosis and a high mortality rate. Although incorporating the anti‑angiogenic agent bevacizumab into treatment protocols has led to enhanced survival rates, a significant number of patients with disease progression following initial platinum‑based chemotherapy have limited therapeutic options. This paper aims to provide an overview of the current progress in cervical cancer treatment strategies, with a focus on the most relevant, potentially practice‑changing results of recent phase III clinical trials.
These data suggest that pembrolizumab combined with chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS and a favorable trend in OS compared with placebo plus chemoradiotherapy and had a manageable safety profile in patients with high‑risk, treatment‑naïve, locally advanced cervical cancer.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- AI approach outperformed human experts in identifying cervical precancer